NEWS: 公告在东京证券交易所JASDAQ标准市场新上市

表纸
市场调查报告书

囊状纤维化症:契约分析报告

Cystic Fibrosis -deals Analytics Report, 2010 to 2019

出版商 GervanoRA Data Services LLP 商品编码 816256
出版日期 内容资讯 英文 41 Pages
订单完成后即时交付
价格
囊状纤维化症:契约分析报告 Cystic Fibrosis -deals Analytics Report, 2010 to 2019
出版日期: 2019年03月29日内容资讯: 英文 41 Pages
简介

本报告提供全球囊状纤维化症治疗相关契约形势相关分析,契约类型,契约额,地区,及中介者为基础的分析,各年度分析,及主要契约的案例研究等。

第1章 简介

第2章 摘要整理

第3章 分析:各类型契约

  • 协定
  • 合作
  • M&A
  • 融资 - 津贴、支援契约
  • 授权契约
  • 联盟契约

第4章 分析:各契约额、地区

第5章 分析:各企业

第6章 分析:各年度频率

第7章 案例研究:有前途的契约前五名

  • 契约1:ROYALTY PHARMA 发表囊状纤维化症治疗的33亿美元的权利金交易
  • 契约2:ASTRAZENECAPFIZER出售小分子抗生素事业
  • 契约3:VERTEX PARION SCIENCES 针对囊状纤维化症以及其他肺部疾病的表皮性Na通道 (ENAC) 抑制剂的开发联盟
  • 契约4:VERTEX MODERNA为了发现、开发囊状纤维化症mRNA治疗药进行独占性地契约
  • 契约5:VERTEX CRISPR THERAPEUTICS 面向遗传基因疾病的新的治疗药的发现、开发CRISPR-CAS9 应该利用遗传基因编辑技术联盟

第8章 简称

目录
Product Code: GERPD001

GervanoRA's ‘Cystic Fibrosis Deals Activity Report, 2010-2019’ has analyzed and provided an understanding of the overall competition in partnering landscape in the disease area that has occurred from the year 2010.

GervanoRA has analyzed more than 90 drug candidates in the current development pipeline. Hence, a number of emerging and clinical-stage companies are embarking with collaborations or partnerships with different pharma companies to aid in the development process of their respective drug candidates. In the light of rocketing competition, not only companies, but also universities, institutes and research centers are getting actively involved in the advancements of new medicines for the treatment of the disease.

The report through its meticulous analysis on global therapeutic landscape of Cystic Fibrosis deals assists companies in taking future partnering decisions based on competitor's R&D activities; current trends in partnering landscape in order to avoid or mitigate competitive market risks.

For a proper understanding, GervanoRA has segmented the report into sections based on:

  • Analytics based on deal type,
  • Analytics based on deal by value,
  • Analytics based on geography
  • Analytics based on deal maker
  • Year-by-year analytics

The report also includes case studies provided for the deals that were prominent and unique among all the deals.

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. REPORT DESCRIPTION
  • 1.2. METHODOLOGY
  • 1.3. OTHER AVAILABLE DEALS ANALYSIS REPORTS
  • 1.4. ABOUT US: GERVANORA DATA SERVICES

2. EXECUTIVE SUMMARY

3. ANALYTICS BY DEAL TYPE

  • 3.1. CYSTIC FIBROSIS AGREEMENTS
  • 3.2. CYSTIC FIBROSIS COLLABORATIONS
  • 3.3. CYSTIC FIBROSIS MERGERS & ACQUISITIONS
  • 3.4. CYSTIC FIBROSIS FINANCING- GRANT AND FUNDING DEALS
  • 3.5. CYSTIC FIBROSIS LICENSING DEALS
  • 3.6. CYSTIC FIBROSIS ALLIANCE DEAL

4. ANALYTICS BY DEAL VALUE AND GEOGRAPHY

5. ANALYTICS BY ACTIVE PLAYERS

6. ANALYTICS BY ANNUAL FREQUENCY

7. CASE STUDIES- TOP FIVE PROMINENT DEALS

  • DEAL 1: ROYALTY PHARMA ANNOUNCES $3.3 BN ROYALTY TRANSACTION WITH CYSTIC FIBROSIS FOUNDATION THERAPEUTICS
  • DEAL 2: ASTRAZENECA TO SELL SMALL MOLECULE ANTIBIOTICS BUSINESS TO PFIZER
  • DEAL 3: VERTEX AND PARION SCIENCES ESTABLISH COLLABORATION TO DEVELOP EPITHELIAL SODIUM CHANNEL (ENAC) INHIBITORS IN CYSTIC FIBROSIS AND OTHER PULMONARY DISEASES
  • DEAL 4: VERTEX AND MODERNA ESTABLISH EXCLUSIVE COLLABORATION TO DISCOVER AND DEVELOP MRNA THERAPEUTICS FOR CYSTIC FIBROSIS
  • DEAL 5: VERTEX AND CRISPR THERAPEUTICS ESTABLISH COLLABORATION TO USE CRISPR-CAS9 GENE EDITING TECHNOLOGY TO DISCOVER AND DEVELOP NEW TREATMENTS FOR GENETIC DISEASES

8. ABBREVIATIONS

LIST OF TABLES

  • TABLE 01: MAJOR AGREEMENTS IN THE CYSTIC FIBROSIS AREA
  • TABLE 02: MAJOR COLLABORATIONS IN THE CYSTIC FIBROSIS AREA
  • TABLE 03: MAJOR COLLABORATIONS IN THE CYSTIC FIBROSIS AREA
  • TABLE 04: MAJOR FINANCING DEALS- GRANTS AND FUNDING IN THE CYSTIC FIBROSIS AREA
  • TABLE 05: MAJOR LICENSING DEALS IN THE CYSTIC FIBROSIS AREA
  • TABLE 06: TOP 10 MAJOR DEALS IN THE CYSTIC FIBROSIS AREA RANKED BY DEAL AMOUNT

LIST OF FIGURES

  • FIGURE 01: CYSTIC FIBROSIS DEALS, BY DEAL TYPE
  • FIGURE 02: CYSTIC FIBROSIS DEAL AMOUNT SHARE BY DEAL TYPE
  • FIGURE 03: CYCTIC FIBROSIS DEALS SCENARIO, YEAR V/S DEAL AMOUNT
  • FIGURE 04: PHARMACEUTICAL COMPANIES INVOLVED IN MORE THAN A SINGLE DEAL IN CF AREA
  • FIGURE 05: NUMBER OF CYSTIC FIBROSIS DEALS, YEAR BY YEAR
  • FIGURE 06: INCREASING AGREEMENT DEALS